The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 345-351

  Van Jaarsveld, Marijn T M ^a   Blijdorp, Iris C J ^b   Boersma, Antonius W M ^a   Pothof, Joris ^a   Mathijssen, Ron H J ^a   Verweij, Jaap ^a   Wiemer, Erik A C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Chemotherapy resistance; Cisplatin; Ovarian cancer; RSK1; RSK2

Indexed keywords

CISPLATIN; RIBOSOMAL S6 KINASE 1; RIBOSOMAL S6 KINASE 2; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; GENE SILENCING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; OVARIAN NEOPLASMS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84872117615     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.08.024     Document Type: Article

References (36)

1. J.A. Ledermann, C. Marth, and M.S. Carey Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 4 2011 763 770
2. R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 6 2009 415 428
3. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 4 2010 765 781
4. Y. Romeo, X. Zhang, and P.P. Roux Regulation and function of the RSK family of protein kinases Biochem J 441 2 2012 553 569
5. T.S. Eisinger-Mathason, J. Andrade, and A.L. Groehler Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival Mol Cell 31 5 2008 722 736
6. T.S. Eisinger-Mathason, J. Andrade, and D.A. Lannigan RSK in tumorigenesis: connections to steroid signaling Steroids 75 3 2010 191 202
7. K.M. Eisenmann, M.W. VanBrocklin, N.A. Staffend, S.M. Kitchen, and H.M. Koo Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad Cancer Res 63 23 2003 8330 8337
8. R. Lara, F.A. Mauri, and H. Taylor An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis Oncogene 30 32 2011 3513 3521
9. S. Kang, S. Elf, and K. Lythgoe P90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells J Clin Invest 120 4 2010 1165 1177
10. S. Kang, S. Dong, and T.L. Gu FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway Cancer Cell 12 3 2007 201 214
11. J.A. Smith, C.E. Poteet-Smith, Y. Xu, T.M. Errington, S.M. Hecht, and D.A. Lannigan Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation Cancer Res 65 3 2005 1027 1034
12. D.E. Clark, T.M. Errington, J.A. Smith, H.F. Frierson Jr., M.J. Weber, and D.A. Lannigan The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation Cancer Res 65 8 2005 3108 3116
13. W. Schmidt, and S.G. Chaney Role of carrier ligand in platinum resistance of human carcinoma cell lines Cancer Res 53 4 1993 799 805
14. S. Goto, K. Yoshida, T. Morikawa, Y. Urata, K. Suzuki, and T. Kondo Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells Cancer Res 55 19 1995 4297 4301
15. T.D. Schmittgen, and K.J. Livak Analyzing real-time PCR data by the comparative C(T) method Nat Protoc 3 6 2008 1101 1108
16. J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res 47 4 1987 936 942
17. H. Burger, W.J. Loos, K. Eechoute, J. Verweij, R.H. Mathijssen, and E.A. Wiemer Drug transporters of platinum-based anticancer agents and their clinical significance Drug Resist Updat 14 1 2011 22 34
18. V.M. Gonzalez, M.A. Fuertes, C. Alonso, and J.M. Perez Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59 4 2001 657 663
19. A. Carriere, H. Ray, J. Blenis, and P.P. Roux The RSK factors of activating the Ras/MAPK signaling cascade Front Biosci 13 2008 4258 4275
20. K.W. Yip, and J.C. Reed Bcl-2 family proteins and cancer Oncogene 27 50 2008 6398 6406
21. B.E. Wilson, E. Mochon, and L.M. Boxer Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis Mol Cell Biol 16 10 1996 5546 5556
22. J.M. Wang, J.R. Chao, W. Chen, M.L. Kuo, J.J. Yen, and H.F. Yang-Yen The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB Mol Cell Biol 19 9 1999 6195 6206
23. Y. Tan, H. Ruan, M.R. Demeter, and M.J. Comb P90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway J Biol Chem 274 49 1999 34859 34867
24. Q.B. She, W.Y. Ma, S. Zhong, and Z. Dong Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation J Biol Chem 277 27 2002 24039 24048
25. A. Bonni, A. Brunet, A.E. West, S.R. Datta, M.A. Takasu, and M.E. Greenberg Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms Science 286 5443 1999 1358 1362
26. E. Dehan, F. Bassermann, and D. Guardavaccaro BetaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis Mol Cell 33 1 2009 109 116
27. R. Anjum, P.P. Roux, B.A. Ballif, S.P. Gygi, and J. Blenis The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling Curr Biol 15 19 2005 1762 1767
28. J. Wu, C.P. Hu, Q.H. Gu, Y.P. Li, and M. Song Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase Acta Pharmacol Sin 31 1 2010 Jan 93 101
29. M. Buck, V. Poli, T. Hunter, and M. Chojkier C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival Mol Cell 8 4 2001 807 816
30. M. Tanabe, H. Izumi, and T. Ise Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines Cancer Res 63 24 2003 8592 8595
31. G. Cai, J. Wang, X. Xin, Z. Ke, and J. Luo Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells Int J Oncol 31 3 2007 657 662
32. K.J. Scanlon, M. Kashani-Sabet, T. Tone, and T. Funato Cisplatin resistance in human cancers Pharmacol Ther 52 3 1991 385 406
33. A. Rebillard, X. Tekpli, and O. Meurette Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells Cancer Res 67 16 2007 7865 7874
34. T. Ohga, K. Koike, and M. Ono Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light Cancer Res 56 18 1996 4224 4228
35. A. Brozovic, and M. Osmak Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance Cancer Lett 251 1 2007 1 16
36. A. Mansouri, L.D. Ridgway, and A.L. Korapati Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells J Biol Chem 278 21 2003 19245 19256